SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
About SAB Biotherapeutics
A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
Company Facts
- Headquarters
- Sioux Falls
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- public
- Employees
- c_00051_00100
- Funding Stage
- ipo
- Total Funding
- $446,320,000
- Last Funding Type
- post_ipo_equity
- Last Funding Date
- 2026-03-17
- Website
- sab.bio
Industries & Categories
Biotechnology, Clinical Trials, Therapeutics
Social Links
Canonical: https://fsome.com/organization/sab-biotherapeutics-58134 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.